TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33477098

Group type: EXPERIMENTAL
Intervention: Sissoo + pineapple system
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Teak + pineapple system
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diverse AFSs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Various AFSs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AFSs with pineapple
Number of subjects: 4
Study: 32212519

Group type: EXPERIMENTAL
Intervention: Fostemsavir (600 mg twice daily)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Fostemsavir plus optimized background therapy
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Open-label fostemsavir plus optimized background therapy
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 371
Study: 35864019

Group type: EXPERIMENTAL
Intervention: Tixel treatment (thermomechanical skin device) applied across the upper and lower eyelids, three treatments with 2-week intervals.
Number of subjects: 40
Study: 32956698

Group type: EXPERIMENTAL
Intervention: Maternal nutrition supplementation initiated preconception (Arm 1)
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Maternal nutrition supplementation initiated at ∼11 weeks of gestation (Arm 2)
Number of subjects: 2421

Group type: COMPARATOR
Intervention: No supplement (Arm 3)
Number of subjects: 2421
Study: 32623637

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study: 35934006

Group type: EXPERIMENTAL
Intervention: Boost after conventional WBI (50 Gy in 25 fractions)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: No boost after conventional WBI (50 Gy in 25 fractions)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Boost after hypofractionated WBI (42.5 Gy in 16 fractions)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: No boost after hypofractionated WBI (42.5 Gy in 16 fractions)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Boost group
Number of subjects: 1608

Group type: COMPARATOR
Intervention: No boost group
Number of subjects: 1608
Study: 33443541

Group type: EXPERIMENTAL
Intervention: Sequential Chemoradiation (SCRT) - cisplatin 60-75 mg/m2 plus paclitaxel 135-175 mg/m2 in a 21-day cycle, given 2 cycles before and 2 cycles after radiotherapy.
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Concurrent Chemoradiation (CCRT) - weekly cisplatin 30-40 mg/m2.
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Radiation Alone (RT) - total dose 45-50 Gy.
Number of subjects: 1048
Study: 34676663

Group type: EXPERIMENTAL
Intervention: Ibrexafungerp (300 mg twice for 1 day)
Number of subjects: 272
Study: 34371163

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32698470

Group type: EXPERIMENTAL
Intervention: Problem-solving based intervention (PSI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 100
Study: 34625800

Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) for 8 weeks
Number of subjects: 51
Study: 33332819

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with an electronic resistive loading device
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional T‐piece protocol (control group)
Number of subjects: 101
Study: 35740145

Group type: EXPERIMENTAL
Intervention: SI + PDT
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: SI + LDD
Number of subjects: 105

Group type: COMPARATOR
Intervention: SI (control)
Number of subjects: 105
Study: 32803438

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment with fluoride varnish
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoride varnish alone (control)
Number of subjects: 60
Study: 33009190

Group type: EXPERIMENTAL
Intervention: CPAP group (5 cmH2O of CPAP during induction and emergence of anaesthesia)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (induction and emergence of anaesthesia without CPAP)
Number of subjects: 42
Study: 32660159

Group type: EXPERIMENTAL
Intervention: Dyadic Pain Management Program (DPMP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (simple pain-related information)
Number of subjects: 64
Study: 34338132

Group type: EXPERIMENTAL
Intervention: GP MDI 36 µg
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: GP MDI 18 µg
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: GP MDI 9 µg
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Open-label tiotropium 2.5 µg
Number of subjects: 1066
Study: 33094562

Group type: EXPERIMENTAL
Intervention: TXA (tranexamic acid) 500 mg into the joint after closure, knee and hip flexed at 45° for 4 h
Number of subjects: 94

Group type: COMPARATOR
Intervention: Physiological saline, limb fully extended
Number of subjects: 94
Study: 34041699

Group type: EXPERIMENTAL
Intervention: Resistance Training Program (RTP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: RTP (participants with VFA values above the median)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 33167908

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 78
Study: 35844853

Group type: EXPERIMENTAL
Intervention: Nomogram developed for predicting overall survival (OS) probabilities.
Number of subjects: 595
Study: 33037989

Group type: EXPERIMENTAL
Intervention: mHealth-supported intervention with individualized goal-setting and Facebook peer support
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group accessing trackers without goal-setting or peer support
Number of subjects: 41
Study: 32156763

Group type: EXPERIMENTAL
Intervention: HEARTPA♀N intervention (integrated smartphone and web-based intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34142273

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latent variable models, growth models, multilevel models
Number of subjects: 0
Study: 32804282

Group type: EXPERIMENTAL
Intervention: Free amplitude movement (FAM) shoulder exercises
Number of subjects: 465

Group type: COMPARATOR
Intervention: Restricted amplitude movement (RAM) shoulder exercises
Number of subjects: 465
Study: 32448015

Group type: EXPERIMENTAL
Intervention: Environmental modifications and assistive device intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Home exercise programmes
Number of subjects: 20
Study: 33124144

Group type: EXPERIMENTAL
Intervention: Continuous ART (CT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: CD4-driven planned treatment interruptions (PTI)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratios
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CD8 cells
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sub-study findings
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Long-term clinical outcomes
Number of subjects: 101
Study: 36348453

Group type: EXPERIMENTAL
Intervention: Intensified TBM regimen (oral high-dose rifampicin 35 mg/kg daily and linezolid 1200 mg daily then 600 mg daily for the first 8 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive aspirin (200 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHO standard TB treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33872986

Group type: EXPERIMENTAL
Intervention: pelacarsen
Number of subjects: 455
Study: 34420048

Group type: EXPERIMENTAL
Intervention: Continuous cuff pressure control (CPC) using an automated electronic device
Number of subjects: 597

Group type: COMPARATOR
Intervention: Intermittent cuff pressure control (CPC) using a manually hand-held manometer
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Continuous CPC
Number of subjects: 597

Group type: COMPARATOR
Intervention: Intermittent CPC
Number of subjects: 597
Study: 33760026

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid gel etchant for 15 seconds
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Etching process
Number of subjects: 27
Study: 32726530

Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 254

Group type: COMPARATOR
Intervention: Uterine-artery embolization
Number of subjects: 254
Study: 35585614

Group type: EXPERIMENTAL
Intervention: Early tracheotomy (≤ 7 days after intubation)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Late tracheotomy (≥ 10 days after intubation)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 150
Study: 34176355

Group type: EXPERIMENTAL
Intervention: Achievement motivation
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Mental health
Number of subjects: 430
Study: 33504356

Group type: EXPERIMENTAL
Intervention: Online treatment decision aid
Number of subjects: 0
Study: 32565534

Group type: EXPERIMENTAL
Intervention: High-dose S-ketamine
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Low-dose S-ketamine
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Racemic ketamine
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 417
Study: 35362913

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) based case management intervention in addition to standard patient-navigation services
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard services only
Number of subjects: 110
Study: 33793754

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 46
Study: 32928863

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NLPE training.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NMES.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo during 8-10 week pulmonary rehabilitation program with NLPE training.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo during 8-10 week pulmonary rehabilitation program with NMES.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (3.2 g per day)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 36208061

Group type: EXPERIMENTAL
Intervention: SBIRT+RMC-PC
Number of subjects: 266

Group type: COMPARATOR
Intervention: SBIRT
Number of subjects: 266
Study: 34706665

Group type: EXPERIMENTAL
Intervention: GnRH-ant half-dose (Group 1)
Number of subjects: 314

Group type: COMPARATOR
Intervention: GnRH-ant full-dose (Group 2)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: BMI < 25 (subgroup C1)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 (subgroup D1)
Number of subjects: 314
Study: 33017045

Group type: EXPERIMENTAL
Intervention: 1,064 nm Q-switched Nd-YAG laser (QSNYL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Modified Kligman's triple combination (TC)
Number of subjects: 28
Study: 34583744

Group type: EXPERIMENTAL
Intervention: Real-time PRO data captured with electronic mobile devices, weekly requests via an app to complete the PRO survey.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care, prompted by the app every 3 months to participate in the PRO survey, no alarm triggered.
Number of subjects: 1000
Study: 33709142

Group type: EXPERIMENTAL
Intervention: Remdesivir (100 mg/day for 5 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 36461653

Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 34752935

Group type: EXPERIMENTAL
Intervention: AT-001 (caficrestat) 1500 mg BID for up to 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched Control Group 1 (MC1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched Control Group 2 (MC2)
Number of subjects: 10
Study: 36346668

Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) meditation app
Number of subjects: 662

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 662
Study: 32027150

Group type: EXPERIMENTAL
Intervention: Reflective parenting program
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 103
Study: 35428973

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3871

Group type: COMPARATOR
Intervention: Multivessel percutaneous coronary intervention (PCI)
Number of subjects: 3871
Study: 34390648

Group type: EXPERIMENTAL
Intervention: Postoperative continuous positive airway pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35781822

Group type: EXPERIMENTAL
Intervention: 1-hour asynchronous video training
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Spaced-education condition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Baseline to post-video
Number of subjects: 84
Study: 33479931

Group type: EXPERIMENTAL
Intervention: Home hospital care (nurse and physician home visits, intravenous medications, remote monitoring, video communication, point‐of‐care testing)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Home hospital care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional hospital care (control)
Number of subjects: 36
Study: 36329548

Group type: EXPERIMENTAL
Intervention: TAU plus hearing aids (n = 42)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Education and advice (treatment as usual, TAU) (n = 41)
Number of subjects: 83
Study: 33772130

Group type: EXPERIMENTAL
Intervention: Ideal facial images on Instagram
Number of subjects: 132

Group type: COMPARATOR
Intervention: Neutral images of nature
Number of subjects: 132
Study: 33545441

Group type: EXPERIMENTAL
Intervention: Early manual rotation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (expectant management)
Number of subjects: 65
Study: 36178723

Group type: EXPERIMENTAL
Intervention: IMB model-based online education program
Number of subjects: 3867

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3867
Study: 32964933

Group type: EXPERIMENTAL
Intervention: Rural children
Number of subjects: 572

Group type: COMPARATOR
Intervention: Urban children
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Rural vs Urban
Number of subjects: 572
Study: 36129719

Group type: EXPERIMENTAL
Intervention: Bilateral standard rTMS
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Bilateral theta burst stimulation (TBS)
Number of subjects: 172
Study: 32520656

Group type: EXPERIMENTAL
Intervention: Dynamic scapular recognition exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35103799

Group type: EXPERIMENTAL
Intervention: Brimonidine 2 mg/mL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/mL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (fellow eyes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brimonidine and Brinzolamide
Number of subjects: 10
Study: 34127741

Group type: EXPERIMENTAL
Intervention: Knowledgeable communities about onagers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Habitat connectivity models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roads cutting off core areas
Number of subjects: 0
Study: 35900549

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin (taxane-based)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin/5FU (non-taxane-based)
Number of subjects: 0
Study: 33221237

Group type: EXPERIMENTAL
Intervention: CAC of >400
Number of subjects: 3075

Group type: EXPERIMENTAL
Intervention: CAC of >100
Number of subjects: 3075
Study: 35808843

Group type: EXPERIMENTAL
Intervention: Endothelial protocol (Nicorandil, L-arginine, folate, Nebivolol, atorvastatin)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Endothelial protocol
Number of subjects: 42
Study: 33357007

Group type: EXPERIMENTAL
Intervention: Salbutamol (16 mg/day) during resistance training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo during resistance training
Number of subjects: 26
Study: 616538626

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 34608719

Group type: EXPERIMENTAL
Intervention: The Growth Factory (TGF)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 34271902

Group type: EXPERIMENTAL
Intervention: Florence (SMS communication system)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 65
Study: 33443925

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) 1300 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oral ε‐aminocaproic acid (EACA) 2000 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Number of subjects: 102
Study: 36380681

Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 204

Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 204
Study: 33447903

Group type: EXPERIMENTAL
Intervention: 3-view radiographic examination
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4-view radiographic examination (including PA scaphoid view)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Individual views (various)
Number of subjects: 58
Study: 32519795

Group type: EXPERIMENTAL
Intervention: Tirzepatide (≥5 mg for non-T2DM and ≥4.5 mg for T2DM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide (5/5/10/10 or 5/5/10/15 mg) in T2DM participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: GIP analogue alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dulaglutide
Number of subjects: 0
Study: 34255711

Group type: EXPERIMENTAL
Intervention: Self-help smartphone app MCT & More for 4 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 400
Study: 36418362

Group type: EXPERIMENTAL
Intervention: Hybrid model HXGBRS
Number of subjects: 554

Group type: COMPARATOR
Intervention: Hybrid model HBPNNRS
Number of subjects: 554

Group type: COMPARATOR
Intervention: Hybrid model HBNRS
Number of subjects: 554

Group type: COMPARATOR
Intervention: Hybrid model HBRS
Number of subjects: 554

Group type: COMPARATOR
Intervention: Hybrid model HRFRS
Number of subjects: 554
Study: 34993458

Group type: EXPERIMENTAL
Intervention: Provision of DAPT score to treating physicians
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control group (no provision of DAPT score)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Provision of DAPT score to treating physicians (DAPT score ≥ 2)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control group (DAPT score < 2)
Number of subjects: 585
Study: 35219222

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program, 8 sessions over 4 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 32252004

Group type: EXPERIMENTAL
Intervention: rhIGF-I with oral estrogen-progesterone (EP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhIGF-I alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhIGF-I and EP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither
Number of subjects: 0
Study: 33879005

Group type: EXPERIMENTAL
Intervention: Treatment-resistant depression (TRD)
Number of subjects: 10449
Study: 35634818

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (PRODET®), 12-week program, 2 days/week for 50 minutes
Number of subjects: 67
Study: 35588245

Group type: EXPERIMENTAL
Intervention: 600 mg/day viloxazine extended-release
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 32274541

Group type: EXPERIMENTAL
Intervention: Standard of care (SOC) + radiotherapy to the prostate (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy (MDT)
Number of subjects: 0
Study: 34581608

Group type: EXPERIMENTAL
Intervention: AI algorithm
Number of subjects: 1531

Group type: COMPARATOR
Intervention: No AI algorithm (Control)
Number of subjects: 1531
Study: 33231117

Group type: EXPERIMENTAL
Intervention: Behavioral approaches to aphasia treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive brain stimulation techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy options
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled behavioral treatments
Number of subjects: 0
Study: 33037974

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 36180765

Group type: EXPERIMENTAL
Intervention: Cytotoxic edema (CE) detected within 7-12 days after symptom onset
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytotoxic edema (CE) within 7-12 days
Number of subjects: 20
Study: 33440966

Group type: EXPERIMENTAL
Intervention: Special position cushion (experimental group)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Conventional hip sponge pads (control group)
Number of subjects: 450
Study: 35277436

Group type: EXPERIMENTAL
Intervention: Participatory Learning and Action (PLA)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 1000
Study: 33576113

Group type: COMPARATOR
Intervention: LTI-291 (3, 10, 30, and 90 mg single doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LTI-291 (3, 10, 30, and 60 mg multiple doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32889869

Group type: EXPERIMENTAL
Intervention: Duodeno-jejunal bypass liner (DJBL)
Number of subjects: 82